2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsCarcinoma, Renal CellHospital MortalityHumansKidney NeoplasmsMedicareRetrospective StudiesTerminal CareUnited StatesConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy use
2009
Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures
Dinan MA, Chou C, Hammill BG, Graham FL, Schulman KA, Telen MJ, Reed SD. Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures. American Journal Of Hematology 2009, 84: 703-709. PMID: 19787790, PMCID: PMC2783350, DOI: 10.1002/ajh.21520.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh-volume surgical proceduresHip replacementMedian ageInpatient costsCell diseaseSurgical proceduresClinical Classification Software codesMore health care resourcesLonger hospital stayHigher inpatient costsNationwide Inpatient SampleLength of stayMultivariable regression analysisHealth care resourcesRegression analysisHospital mortalityHospital stayInpatient outcomesInpatient mortalitySurgical patientsInpatient staySCD cohortInpatient SampleProcedural characteristics